BioVie Inc (BIVI)
1.12
-0.11
(-8.94%)
USD |
NASDAQ |
May 09, 16:00
1.12
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 20.67M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -77.48% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.8639 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.84% |
Profile
Edit
| BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |
| URL | https://www.bioviepharma.com |
| Investor Relations URL | https://bioviepharma.com/investors/ |
| HQ State/Province | Nevada |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 14, 2025 (est.) |
| Last Earnings Release | Feb. 11, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer’s disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |
| URL | https://www.bioviepharma.com |
| Investor Relations URL | https://bioviepharma.com/investors/ |
| HQ State/Province | Nevada |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | May. 14, 2025 (est.) |
| Last Earnings Release | Feb. 11, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |